|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Next-generation sequencing (NGS) revealing BRD4-NUT fusion, and NUT immunohistochemistry confirmed the diagnosis of NC.
|
30307375 |
2019 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The diagnosis of NUT carcinoma was confirmed by the identification of BRD4-NUT fusion.
|
30782401 |
2019 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interestingly, we found that miR-3140 downregulated the BRD4-NUT fusion protein and suppressed in vitro tumor cell growth in a NMC cell line, Ty-82 cells.
|
29540837 |
2018 |
|
NUT midline carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
NUT carcinoma (NC) shows very aggressive clinical behavior, occurs predominantly in the thorax and head and neck region of children and adults, and is defined by the presence of NUT (aka NUTM1) rearrangement, mostly BRD4-NUTM1 fusion resulting from t(15;19)(q13; p13.1).
|
29700887 |
2018 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, ectopic expression of BRD4-NUT in a non-NC cell line induces sequestration of Z4 factors to BRD4-NUT foci.
|
30139738 |
2018 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A high-throughput drug screen confirmed that microtubule inhibitors, topoisomerase inhibitors and anthracyclines are highly cytotoxic in the majority of NMC lines, and that cell lines expressing the <i>BRD4-NUTM1</i> (exon11:exon2) variant are an order of magnitude more responsive to bromodomain inhibitors (iBETs) on average than those with other <i>BRD4-NUTM1</i> translocation variants.
|
29348827 |
2017 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Importantly, this program is directed independently and also reciprocally to the growth-promoting properties of BRD4 and is potently repressed by BRD4-NUT, a driver of NUT midline carcinoma.
|
28525743 |
2017 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we discovered that BRD4 is hyperphosphorylated in NUT midline carcinoma and identified CDK9 as a potential kinase mediating BRD4 hyperphosphorylation.
|
28630312 |
2017 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results support a model in which NMC is dependent on ectopic NUT-mediated interactions between EP300 and components of BRD4 regulatory complexes, leading to a cascade of misregulation.
|
28484033 |
2017 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
By interrogating the activity of 1,505 kinase inhibitors, we found that BRD4-NUT-rearranged NUT midline carcinoma (NMC) cells are specifically killed by CDK9 inhibition (CDK9i) and depend on CDK9 and Cyclin-T1 expression.
|
28930680 |
2017 |
|
NUT midline carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A biopsy showed an adenocarcinoma fetal type/lung blastoma, so a left inferior lobectomy was performed: NMC harboring BRD4-NUT rearrangement was diagnosed.
|
28967088 |
2017 |
|
NUT midline carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The most successful approaches that have been clinically validated so far include the targeting of the BRD4-NUT fusion transcript in NUT-midline carcinoma by BET (Bromodomain Extra-Terminal) inhibitors, and the use of EZH2 (Enhancer of Zest Homolog 2) inhibitors in SMARCB1-deficient malignant rhabdoid tumors and SMARCA4-deficient ovarian small cell carcinomas.
|
28426098 |
2017 |
|
NUT midline carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We present the first clinical proof-of-concept that targeting BRD4-NUT with a BET inhibitor results in impressive and rapid antitumor activity in NMC.
|
26976114 |
2016 |
|
NUT midline carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A striking case of a chromatin-centric disease is NUT-midline carcinoma (NMC), which is characterized by expression of NUT as a fusion partner most frequently with BRD4.
|
27698495 |
2016 |
|
NUT midline carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Nuclear protein in testis (NUT) midline carcinoma (NMC) is a rare cancer that displays a characteristic chromosomal rearrangement of BRD4-NUT t(15;19)(q14;q13.1).
|
26402248 |
2015 |
|
NUT midline carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These "megadomains" appear to be the result of aberrant, feed-forward loops of acetylation and binding of acetylated histones that drive transcription of underlying DNA in NMC patient cells and naïve cells induced to express BRD4-NUT.
|
26220994 |
2015 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, these findings suggest that MYC is a downstream target of BRD4-NUT that is required for maintenance of NMC cells in an undifferentiated, proliferative state.
|
23604113 |
2014 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study provides new mechanistic insights for understanding how alteration of BRD4 function by BRD4-NUT oncogene leads to the highly malignant NMC carcinoma.
|
24736545 |
2014 |
|
NUT midline carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here we describe a classic NMC with a BRD4-NUT fusion gene in a middle-aged woman.
|
24326851 |
2014 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We find further that NSD3 is required for the blockade of differentiation in BRD4-NUT-expressing NMCs.
|
24875858 |
2014 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.
|
23128391 |
2013 |
|
NUT midline carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Reverse transcription polymerase chain reaction analysis and subsequent direct sequencing revealed that the bromodomain-containing protein 4-NUT chimeric gene was present in tumor tissue of both patients, leading to a diagnosis of NMC.
|
22301500 |
2012 |
|
NUT midline carcinoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Pathogenesis of NUT midline carcinoma.
|
22017582 |
2012 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study provides a novel mechanism by which the BRD4-NUT oncogene perturbs BRD4 functions to block cellular differentiation and to contribute to the oncogenic progression in the highly aggressive NMC.
|
21652721 |
2011 |
|
NUT midline carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two new cases of NMC containing BRD4-NUT fusions were detected by C52 IHC, but missed by conventional FISH.
|
19363441 |
2009 |